FDA approve's Dendreon's Provenge

PR Newswire logoImage via Wikipedia

Here's Dendreon's newswire on it's approval of Provenge. Stock hit an all time high of 57.55 and has tapered off a bit around the 53 point range. This is a quality stock and it's profits should help the bottom line with this big news on April 29th, 2010.

SEATTLE, April 29, 2010 /PRNewswire via COMTEX/ --Dendreon Corporation (Nasdaq: DNDN ) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE(R)
(sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class known as autologous cellular immunotherapies.